Home Tags Biotechnology
BioBuilder and K2 Scientific Bring Synthetic Biology Programs and Laboratory Equipment to High-Need High Schools Around the Country
BOSTON, Mass., Nov. 18, 2022 (SEND2PRESS NEWSWIRE) -- As a world-recognized program that trains the next generation of innovators and skilled workers in synthetic biology, the BioBuilder Educational Foundation announced new work with K2 Scientific to make high quality tools and equipment for life science research widely accessible. BioBuilder has partnered with K2 Scientific, who will donate industry-grade refrigeration units to four high-need high schools participating in the BioBuilderClub this academic year.
SCOTTSDALE, Ariz., Oct. 18, 2022 (SEND2PRESS NEWSWIRE) -- Dosaggio™ by SottoPelle® and PatientNow announced today that they have entered into a partnership that integrates the two companies' innovative technologies, to improve efficiencies and elevate patient care for providers offering bioidentical hormone replacement therapy (BHRT).
SCOTTSDALE, Ariz., Sept. 28, 2022 (SEND2PRESS NEWSWIRE) -- Dosaggio™ by SottoPelle® and Cerbo announced today that they have entered into a partnership that integrates the two companies' innovative technologies, to improve efficiencies and elevate patient care for providers offering bioidentical hormone replacement therapy (BHRT).
BioBuilder funded to expand student opportunity in rural and urban areas through its collaborative after school program
BOSTON, Mass., Sept. 20, 2022 (SEND2PRESS NEWSWIRE) -- Thanks to a two-year grant recently awarded by BioMADE, the BioBuilder Educational Foundation will expand a program that has supported thousands of high school inventors over the last decade. BioBuilder is leading the project, "Launching High School Bioengineers on their Paths to College and Careers," with funding that will bring the authentic tools and approaches for engineering biology to BioBuilderClub students nationwide in collaboration with East Tennessee State University, Ars Biotechnica, and Daicel Arbor Biosciences.
AUSTIN, Texas, Sept. 13, 2022 (SEND2PRESS NEWSWIRE) -- Kalyagen is pleased to announce that it will be attending and its founder, Christian Drapeau, will be speaking at the upcoming 8th Annual Biohacking Conference. The conference, which is completely sold out, will be held September 15-17 at The Beverly Hilton in Beverly Hills, California.
Proteios Technology, Inc. Awarded $1.6 Million NIH SBIR Grant to Commercialize its Multivariate Cell Isolation Technology
SEATTLE, Wash., Sept. 8, 2022 (SEND2PRESS NEWSWIRE) -- Proteios Technology, Inc. is pleased to announce it's received a $1.6 million SBIR Phase II grant from the National Institutes of Health (NIH) to commercialize its multivariate (parallel) cell isolation technology. Grant funds will be used to extend Proteios' cell isolation kits to include up to 20 of the most common cell types currently used in cell therapy development.
AUSTIN, Texas, April 29, 2022 (SEND2PRESS NEWSWIRE) -- Kalyagen® is pleased to announce that it will be attending the Fort Lauderdale Open as part of its sponsorship of golf professional Jerrel Gill. The Open will be hosted at the Fort Lauderdale Country Club on May 2-3, 2022.
AUSTIN, Texas, April 27, 2022 (SEND2PRESS NEWSWIRE) -- Kalyagen is pleased to announce that it will be attending and hosting a booth (#121) at the upcoming Paleo f(x)™ 2022 conference to be held in Austin on April 29 - May 1. STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).
Oral Vaccine Boosts COVID Immunity: study conducted on nonhuman primates is published in the journal Vaccine
ROCHESTER, Minn., April 6, 2022 (SEND2PRESS NEWSWIRE) -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine.
Myrio Therapeutics and Pure MHC, LLC Announce Research Collaboration to Develop Novel, Targeted Antibody-Based Cancer Therapies
OKLAHOMA CITY, Okla., AUSTIN, Texas and MELBOURNE, Australia, April 6, 2022 (SEND2PRESS NEWSWIRE) -- Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC's proprietary offering of MHC peptide targets for oncology with Myrio's revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.
GENEVA, Switzerland, and NEW YORK, N.Y., April 5, 2022 (SEND2PRESS NEWSWIRE) -- Neurosoft Bioelectronics, an early-stage company developing tools for unmet needs in epilepsy and tinnitus, was awarded nearly $3 million USD, from the SERI-Funded European Innovation Council Accelerator Grant and a share of the $165,000 USD through the European Research Council Proof-of-Concept Grant.
NEW YORK, N.Y., March 28, 2022 (SEND2PRESS NEWSWIRE) -- Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that founders and CEOs of several promising bioelectronic medicine startups will present at the Fifth Annual Bioelectric Medicine Forum on April 5, 2022. The event will take place in New York City, although participation via Zoom videoconference will be accommodated.
Kalyagen Announces Supporting Partnership of Two South Florida PGA Events and PGA Associate Jerrel Gill
AUSTIN, Texas, March 10, 2022 (SEND2PRESS NEWSWIRE) -- Kalyagen® is pleased to announce that it is a supporting partner of two upcoming South Florida PGA Section events and golf professional Jerrel Gill. The two events are the South Florida PGA Foundation PGA HOPE Classic on May 12, 2022 and the South Florida Open on June 21-23, 2022.
Pure Transplant Solutions, LLC and Vall d’Hebron University Hospital Announce Research Collaboration
AUSTIN, Texas and BARCELONA, Spain, Feb. 15, 2022 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with Vall d'Hebron Barcelona Hospital Campus to develop new technologies for B-cell monitoring in transplant rejection.
Pure Transplant Solutions, LLC and Oxford Immunotec, Ltd. Announce Exclusive Sublicense Agreement to Support Commercialization of Novel B Cell Measurement Assay...
AUSTIN, Texas and OXFORD, U.K., Dec. 7, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a developer of novel HLA based transplant diagnostics, and Oxford Immunotec, Ltd. (OI), a global diagnostics company part of PerkinElmer Inc., today announce an exclusive sublicense agreement in which PTS will obtain exclusive commercial rights to issued patents protecting a novel assay originally developed by Dr. Oriol Bestard, M.D., Ph.D.
SAN FRANCISCO, Calif., Nov. 8, 2021 (SEND2PRESS NEWSWIRE) -- Neurotech Reports, the San Francisco, California publisher of market intelligence for the healthcare industry, announced the launch of a new monthly newsletter covering the bioelectronic medicine industry, one of the newest and fastest growing industry segments. The publication, BioElectRx Business Report, is the first industry newsletter devoted to bioelectronic medicine.
AUSTIN, Texas, Oct. 12, 2021 (SEND2PRESS NEWSWIRE) -- Kalyagen is pleased to announce the successful product registration of STEMREGEN® in Spain. This announcement coincides with Christian Drapeau's, CEO and Chief Scientist of Kalyagen, trip to Madrid, Spain last week to speak at the IV Jornadas Internacionales Otto H. Warburg symposium at the NH Madrid Príncipe de Vergara.
iCell Gene Therapeutics Announces cCAR-T Clinical Publication in the Stem Cell Reviews and Reports Journal
STONY BROOK, N.Y., Sept. 10, 2021 (SEND2PRESS NEWSWIRE) -- iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, today announced the publication of their clinical study utilizing cCAR T-cell immunotherapy to successfully treat a patient with lupus.
ROCHESTER, Minn., Aug. 24, 2021 (SEND2PRESS NEWSWIRE) -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced the appointment of leading life sciences investor Harry Hoffman to the Company's board of directors.
LOS ANGELES, Calif., Aug. 11, 2021 (SEND2PRESS NEWSWIRE) -- Integrity Bio, Inc., a privately held formulation and fill-finish organization, was sold to Curia (formerly Albany Molecular Research, Inc. (AMRI)), a Contract Development and Manufacturing Organization (CDMO) and leading global provider of advanced contract research, development, and manufacturing solutions. KROST, a Los Angeles-based firm, acted as the exclusive financial advisor to Integrity Bio in the transaction.